Parkinson disease (PD) is the second most common neurodegenerative disorder, affecting>
1% of the population≥ 65 years of age and with a prevalence set to double by 2030. In …

Introduction COVID-19 has a wide range of clinical manifestations. Neurological
manifestations in COVID-19 patients were demonstrated during the pandemic, including …

A growing awareness about brain health and Alzheimer's disease in the general population
is leading to an increasing number of cognitively unimpaired individuals, who are concerned …

This article describes the public health impact of Alzheimer's disease (AD), including
incidence and prevalence, mortality and morbidity, costs of care, and the overall impact on …

Although dementia has been described in ancient texts over many centuries (eg,“Be kind to
your father, even if his mind fail him.”–Old Testament: Sirach 3: 12), our knowledge of its …

The world's population is aging, bringing about an ever‐greater burden of mental disorders
in older adults. Given multimorbidities, the mental health care of these people and their …

Background Blood-based biomarkers for Alzheimer's disease (AD) might facilitate
identification of participants for clinical trials targeting amyloid beta (Abeta) accumulation …

Although the prevalence of dementia continues to increase worldwide, incidence in the
western world might have decreased as a result of better vascular care and improved brain …

The diagnosis of Alzheimer's disease can be improved by the use of biological measures.
Biomarkers of functional impairment, neuronal loss, and protein deposition that can be …

During the past decade, a conceptual shift occurred in the field of Alzheimer's disease (AD)
considering the disease as a continuum. Thanks to evolving biomarker research and …